TransMedics Group (TMDX) Stock Forecast & Price Target

Compare

1,678 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TMDX Analyst Ratings

Strong Buy

8 Buy

2 Hold

0 Sell

Based on 10 analysts giving stock ratings to

TransMedics

Group

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TMDX Stock 12 Month Forecast

Average Price Target

$143.67

▲(14.95% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for TransMedics Group in the last 3 months. The average price target is $143.67 with a high forecast of $170.00 and a low forecast of $115.00. The average price target represents a 14.95% change from the last price of $124.98.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"61":"$61","116":"$116","171":"$171","88.5":"$88.5","143.5":"$143.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":170,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$170.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":143.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$143.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":115,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$115.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[61,88.5,116,143.5,171],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,131.54,134.49846153846153,137.45692307692306,140.4153846153846,143.37384615384616,146.3323076923077,149.29076923076923,152.24923076923076,155.2076923076923,158.16615384615383,161.12461538461537,164.08307692307693,167.04153846153847,{"y":170,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,131.54,132.47307692307692,133.40615384615384,134.33923076923077,135.2723076923077,136.20538461538462,137.13846153846154,138.07153846153844,139.00461538461536,139.9376923076923,140.8707692307692,141.80384615384614,142.73692307692306,{"y":143.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,131.54,130.2676923076923,128.9953846153846,127.72307692307692,126.45076923076923,125.17846153846153,123.90615384615384,122.63384615384615,121.36153846153846,120.08923076923077,118.81692307692308,117.54461538461538,116.27230769230769,{"y":115,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":82.4,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.14,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.55,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.32,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.27,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.94,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.1,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.55,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.89,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.54,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$170.00

Average Price Target$143.67

Lowest Price Target$115.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Lila Implantra

TR | OpenAI - 4o

$154→$153

Buy

22.42%

Upside

Reiterated

11/05/25

AI Generated ArticleAI Generated Article

Suraj Kalia

Oppenheimer

$150

Buy

20.02%

Upside

Reiterated

11/03/25

Oppenheimer Remains a Buy on TransMedics Group (TMDX)

Daniel Markowitz CFA

Evercore ISI

$155

Buy

24.02%

Upside

Reiterated

10/30/25

Evercore ISI Reaffirms Their Buy Rating on TransMedics Group (TMDX)

Patrick Wood

Morgan Stanley

$123

Hold

-1.58%

Downside

Reiterated

10/30/25

Analysts Offer Insights on Healthcare Companies: MiMedx Group (NASDAQ: MDXG), TransMedics Group (NASDAQ: TMDX) and Arcus Biosciences (NYSE: RCUS)Transmedics Group Inc Equal-Weight, PT remains at 123.00.

Michael Matson

Needham

$148

Buy

18.42%

Upside

Reiterated

10/30/25

Analysts Offer Insights on Healthcare Companies: Align Tech (NASDAQ: ALGN), TransMedics Group (NASDAQ: TMDX) and Opko Health (NASDAQ: OPK)

Matthew O'Brien

Piper Sandler

$145→$140

Buy

12.02%

Upside

Reiterated

10/30/25

Piper Sandler Reaffirms Their Buy Rating on TransMedics Group (TMDX)

Ryan Daniels

William Blair

―

Buy

―

Reiterated

10/29/25

TransMedics Group: Strong Financial Performance and Positive Outlook Justify Buy Rating

William Plovanic

Canaccord Genuity

$142→$147

Buy

17.62%

Upside

Reiterated

10/29/25

TransMedics price target raised to $147 from $142 at CanaccordTransMedics price target raised to $147 from $142 at Canaccord

Josh Jennings

TD Cowen

$170

Buy

36.02%

Upside

Reiterated

10/29/25

TD Cowen Reaffirms Their Buy Rating on TransMedics Group (TMDX)

Young Li

Jefferies

$145

Buy

16.02%

Upside

Reiterated

10/28/25

Jefferies Sticks to Its Buy Rating for TransMedics Group (TMDX)

Thomas Stephan

Stifel Nicolaus

$115

Hold

-7.99%

Downside

Reiterated

10/14/25

Stifel Nicolaus Reaffirms Their Hold Rating on TransMedics Group (TMDX)

David Rescott

Robert W. Baird

$148→$152

Buy

21.62%

Upside

Reiterated

07/31/25

TransMedics price target raised to $152 from $148 at BairdTransMedics price target raised to $152 from $148 at Baird

Allen Gong

J.P. Morgan

$81→$114

Hold

-8.79%

Downside

Reiterated

05/09/25

TransMedics Group (TMDX) PT Raised to $114 at JPMorganJPMorgan analyst Allen Gong raised the price target on TransMedics Group (NASDAQ: TMDX) to $114.00 (from $81.00) while maintaining a Neutral rating.

Unknown Analyst

Nephron

Not Ranked

Nephron

$105

Buy

-15.99%

Downside

Initiated

01/06/25

Nephron starts TransMedics Group (TMDX) at BuyNephron initiates coverage on TransMedics Group (NASDAQ: TMDX) with a Buy rating and a price target of $105.00.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Lila Implantra

TR | OpenAI - 4o

$154→$153

Buy

22.42%

Upside

Reiterated

11/05/25

AI Generated ArticleAI Generated Article

Suraj Kalia

Oppenheimer

$150

Buy

20.02%

Upside

Reiterated

11/03/25

Oppenheimer Remains a Buy on TransMedics Group (TMDX)

Daniel Markowitz CFA

Evercore ISI

$155

Buy

24.02%

Upside

Reiterated

10/30/25

Evercore ISI Reaffirms Their Buy Rating on TransMedics Group (TMDX)

Patrick Wood

Morgan Stanley

$123

Hold

-1.58%

Downside

Reiterated

10/30/25

Michael Matson

Needham

$148

Buy

18.42%

Upside

Reiterated

10/30/25

Analysts Offer Insights on Healthcare Companies: Align Tech (NASDAQ: ALGN), TransMedics Group (NASDAQ: TMDX) and Opko Health (NASDAQ: OPK)

Matthew O'Brien

Piper Sandler

$145→$140

Buy

12.02%

Upside

Reiterated

10/30/25

Piper Sandler Reaffirms Their Buy Rating on TransMedics Group (TMDX)

Ryan Daniels

William Blair

―

Buy

―

Reiterated

10/29/25

TransMedics Group: Strong Financial Performance and Positive Outlook Justify Buy Rating

William Plovanic

Canaccord Genuity

$142→$147

Buy

17.62%

Upside

Reiterated

10/29/25

TransMedics price target raised to $147 from $142 at CanaccordTransMedics price target raised to $147 from $142 at Canaccord

Josh Jennings

TD Cowen

$170

Buy

36.02%

Upside

Reiterated

10/29/25

TD Cowen Reaffirms Their Buy Rating on TransMedics Group (TMDX)

Young Li

Jefferies

$145

Buy

16.02%

Upside

Reiterated

10/28/25

Jefferies Sticks to Its Buy Rating for TransMedics Group (TMDX)

Thomas Stephan

Stifel Nicolaus

$115

Hold

-7.99%

Downside

Reiterated

10/14/25

Stifel Nicolaus Reaffirms Their Hold Rating on TransMedics Group (TMDX)

David Rescott

Robert W. Baird

$148→$152

Buy

21.62%

Upside

Reiterated

07/31/25

TransMedics price target raised to $152 from $148 at BairdTransMedics price target raised to $152 from $148 at Baird

Allen Gong

J.P. Morgan

$81→$114

Hold

-8.79%

Downside

Reiterated

05/09/25

Unknown Analyst

Nephron

Not Ranked

Nephron

$105

Buy

-15.99%

Downside

Initiated

01/06/25

Nephron starts TransMedics Group (TMDX) at BuyNephron initiates coverage on TransMedics Group (NASDAQ: TMDX) with a Buy rating and a price target of $105.00.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering TransMedics Group

1 Month

xxx

Success Rate

19/31 ratings generated profit

Average Return

+6.41%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 61.29% of your transactions generating a profit, with an average return of +6.41% per trade.

3 Months

xxx

Success Rate

20/31 ratings generated profit

Average Return

+16.84%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.52% of your transactions generating a profit, with an average return of +16.84% per trade.

1 Year

William PlovanicCanaccord Genuity

Success Rate

24/31 ratings generated profit

Average Return

+56.34%

reiterated a buy rating 10 days ago

Copying William Plovanic's trades and holding each position for 1 Year would result in 77.42% of your transactions generating a profit, with an average return of +56.34% per trade.

2 Years

xxx

Success Rate

28/31 ratings generated profit

Average Return

+105.15%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 90.32% of your transactions generating a profit, with an average return of +105.15% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TMDX Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TMDX has received 31 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. TMDX average Analyst price target in the past 3 months is 143.67.

Each month's total comprises the sum of three months' worth of ratings.

TMDX Financial Forecast

TMDX Earnings Forecast

Next quarter’s earnings estimate for TMDX is $0.38 with a range of $0.22 to $0.62. The previous quarter’s EPS was $0.66. TMDX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year TMDX has Preformed in-line its overall industry.

TMDX Sales Forecast

Next quarter’s sales forecast for TMDX is $156.41M with a range of $155.00M to $160.10M. The previous quarter’s sales results were $143.82M. TMDX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year TMDX has Preformed in-line its overall industry.

TMDX Stock Forecast FAQ

What is TMDX’s average 12-month price target, according to analysts?

Based on analyst ratings, TransMedics Group Inc’s 12-month average price target is 143.67.

What is TMDX’s upside potential, based on the analysts’ average price target?

TransMedics Group Inc has 14.95% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TMDX a Buy, Sell or Hold?

TransMedics Group Inc has a consensus rating of Strong Buy which is based on 8 buy ratings, 2 hold ratings and 0 sell ratings.

What is TransMedics Group Inc’s price target?

The average price target for TransMedics Group Inc is 143.67. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $170.00 ,the lowest forecast is $115.00. The average price target represents 14.95% Increase from the current price of $124.98.

What do analysts say about TransMedics Group Inc?

TransMedics Group Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of TMDX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

TransMedics Group (TMDX) Stock Forecast & Price Target

TMDX Analyst Ratings

TMDX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering TransMedics Group

TMDX Analyst Recommendation Trends

TMDX Financial Forecast

TMDX Earnings Forecast

TMDX Sales Forecast

TMDX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts